Kornimate/medical-research-clean huggingface dataset:
effect mode of delivery and feeding on body composition and nutritional status of children

Conditions: Child Obesity

Summary: * feeding and growth during infancy have been associated with later life body mass index. * breastfeeding seems to have a small but consistent protective effect against obesity in children. * the cholesterol content of human milk is 6-fold greater than that of the standard infant formulas. * infants delivered by caesarean section may be at increased risk of childhood obesity and adulthood obesity.

* previous guidelines recommended that infants who are exclusively breast fed for the first 6 months of life, with particular solid foods gradually introduced from 6 months associated with lower childhood fat mass. * the stated reason for discouraging introduction of solids to infant before 4 months include the risk of excessive weight gain, vulnerability of the gut to infection and increased susceptibility to the development of allergic disease. * infants whose dietary pattern was most similar to feeding guidelines, with high frequencies of fresh fruit and vegetables, home prepared foods and breast milk, gained weight and skin fold thickness more rapidly from 6 to12 months than other infants, independent of milk feeding, age of introduction of solids and maternal factors. * exclusively breastfed infants had significantly higher total cholesterol (tc) level and low density lipoprotein level (ldl) and lower high density lipoprotein level (hdl) as compared to mixed-fed infants in the first 6 months of life. * exclusive breast feeding seems to have a protective effect against some risk factors for cardiovascular disease in later life, as those who exclusively breastfed had lower level of plasma low density lipoprotein (ldl) cholesterol conc., higher level of high density lipoprotein (hdl) and lower ldl/hdl ratio than those bottle fed. * early weaning is related to rapid weight gain in infancy, and this may have implication for childhood obesity. * vaginally delivered children are colonised with bacterial strains from the mothers' vagina during delivery in contrast to children delivered by cs, and these differences seem to persist throughout infancy. * the gut microbiota may have a role in energy harvesting, hence inoculation with maternal microbiota through vaginal delivery may be protective for childhood overweight compared with delivery by cs.

Eligibility criteria:
inclusion criteria: * infants of both sexes * infants from 2 to 3 years * breast fed or formula fed or mixed fed infants exclusion criteria: * children less than 2 and more than 3 years ago. * children having family history of chronic illness * children having family history of metabolic * children fed cow milk or buffalo milk. * infants delivered preterm.
dietary intervention with the modified atkins diet in stroke rehabilitation

Conditions: Stroke; Ischemic Stroke

Summary: this phase 1 study tests whether use of the modified atkins diet (mad) can improve motor impairment after stroke. it is based on the hypothesis that after stroke, the brain's utilization of glucose, it's primary source of energy, is disrupted. the mad is a low-carbohydrate diet that has can switch the body's metabolism from using glucose to using products of fat metabolism, so-called ketones. ketones may act as an alternative energy substrate for the brain. ketones also have several neuroprotective effects after stroke.


Eligibility criteria:
inclusion criteria: * age 18-99 * first time unilateral hemispheric ischemic stroke. not more than 12 weeks after acute stroke. * burke stroke rehabilitation unit inpatient. * preserved cognitive ability to understand commands and participate in outcome measures and to give informed consent. in patients with aphasia, cognitive ability to give consent will be determined by a physician. * upper extremity motor impairment with an ue fugl meyer score ≤ 56/66 * independence in adls/ absence of major impairment prior to stroke exclusion criteria: * hemorrhagic stroke * uncontrolled hyperlipidemia with ldl \> 250 on admission * uncontrolled diabetes mellitus with bs \> 300 averaged over the first day of admission * nutritional risk as defined by bmi \< 18.5 or by a score of 2 or higher on the malnutrition universal screening tool (scores bmi, % of unplanned weight loss in last 3-6 months and question whether patient is acutely ill) * decreased renal function with egfr \<30% * stage iii and iv pressure ulcers * osteoporosis not sufficiently treated with oral calcium and vitamin d supplements * chf as defined by class iii or worse * hypersensitivity/allergy to cholesterol lowering medications * h/o kidney stones within last 1 year prior to stroke or medications predisposing to kidney stones such as topamax, carboanhydrase inhibitors * inability to tolerate an oral diet and need for tube feeds * active enrollment in any other interventional studies at burke; enrollment in observational studies or studies using tms as a measurement may not pose exclusion criteria * cognitively unable to follow instructions.

Keywords: stroke ketones ketogenic diet impairment disability
low-dose il-2 ( interleukin-2) treatment in macrophage activation syndrome（mas）

Conditions: Macrophage Activation Syndrome

Summary: the investigators evaluate the effectiveness and safeness of low-dose recombinant human interleukin-2 （rhil-2） for mas.

autoimmune-associated macrophage activation syndrome (mas), also known as secondary hemophagocytic lymphohistiocytosis (hlh), is a rapidly progressing life-threatening disease. vp16 (etoposide) is a well-known standard therapy, but is associated with substantial adverse effects, especially myelosuppression and infections , while steroids and ciclosporin (csa) are not always efficient in this disease. the investigators hypothesized that low- dose il-2 could be a novel therapy in mas. this clinical study will test the efficacy and safety of low dose il-2 treatment in mas. the investigators perform a single-centre pilot trial with rhil-2 in mas. the investigators evaluate the effectiveness and safeness of low-dose il-2 for mas.

Eligibility criteria:
inclusion criteria: * diagnosis of macrophage activation syndrome（mas） * mas secondary to autoimmune disease, such as adult onset still's disease (aosd), juvenile rheumatoid arthritis (jra) or systemic lupus erythematosus (sle). exclusion criteria: * primary mas * secondary to neoplasia, lymphoma and virus infection * pre-treatment with cyclosporine a * relevant cardiac, pulmonary, neurologic or psychiatric disease * life-vaccination within 4 weeks before begin with study medication * pregnant or breast-feeding * weight under 45kg or more than 80kg
artificial tears versus preservative free ketorolac trometamol 0.45% for acute viral conjunctivitis

Conditions: Conjunctivitis, Viral

Summary: the purpose of this study is to evaluate the evolution of the symptoms of acute viral conjunctivitis using preservative free ketorolac trometamol 0.45% associated with carboxymethylcellulose compared with isolated use of preservative-free artificial tears.

the purpose of this study is to evaluate the evolution of the symptoms of acute viral conjunctivitis using preservative free ketorolac trometamol 0.45% associated with carboxymethylcellulose compared with isolated use of preservative-free artificial tears. a randomized double-masked study will include 60 patients divided into two groups: group 1: using a formulation of ketorolac tromethamine 0.45% associated with carboxymethylcellulose (acular cmc®, allergan, irvine, usa) and group 0: using artificial tears (optive ud®, allergan, irvine, usa), both drugs without preservatives.

Eligibility criteria:
inclusion criteria: * acute conjunctivitis (unilateral or bilateral) for less than two weeks, * signs and symptoms consistent with viral conjunctivitis and at least one of the following: preauricular lymphadenopathy, upper tract respiratory infection or recent contact with someone with conjunctivitis exclusion criteria: * pregnant women * allergies to non-steroidal anti-inflammatories * history of seasonal allergic conjunctivitis * contact lens wearers * history of ocular herpes infection * blepharitis * severe dry eye * purulent discharge * defects in the corneal epithelium

Keywords: conjunctivitis, viral ketorolac artificial tears
the effects of co-admin of colesevelam and sitagliptin on glucose metabolism in subjects with type 2 diabetes mellitus

Conditions: Diabetes Mellitus, Type 2

Summary: this study will assess the effects of colesevelam, alone or in combination with sitagliptin, on glucose metabolism in subjects with t2dm inadequately controlled by diet and exercise

the hypothesis is that co-administrationof colesevelam plus sitagliptin results in a greater reduction in hba1c compared to colesevelam hcl treatment by 1. improving the effects of colesevelam on fasting glucose metabolism 2. improving the effects of colsevelam on postprandial glucose metabolism

Eligibility criteria:
inclusion criteria: * male or female * females of childbearing potential are on approved birth control method * negative pregnancy testing for females of childbearing potential * previously diagnosed or newly diagnosed with t2dm drug naïve subjects * hba1c: 6.7-10% * age 18 - 80 years * bmi ≥ 18.5 kg/m2 and ≤ 40 kg/m2 * fasting serum glucose \< 300 mg/dl * normal liver function, normal thyroid function, no history of liver, biliary or intestinal disease * normal tsh * on stable diet and exercise routine for at least 4 weeks prior to screening * has had a stable weight (+/-5%) for ≥3 months before screening exclusion criteria: * a history of type 1 diabetes mellitus or history of diabetic ketoacidosis * history of chronic (required daily for \> 2 months) use of insulin therapy * treatment with blood pressure lowering therapy that has not been stable for three months before screening * treatment with lipid lowering medication other than statins * treatment with statins that has not been stable for three months before screening * treatment with a dpp-4 inhibitor or and glp1 agonists at any time * treatment with a thiazolidinedione (tzd) within the last 6 months of screening * history of an allergic or toxic reaction to sitagliptin or colesevelam * history of dysphagia, swallowing disorders, bowel obstruction, intestinal motility disorder, and gastrointestinal disorders * history of major gastrointestinal surgery * history of kidney problems * fasting plasma triglycerides \> 300 mg/dl * serum ldl-c \<60 mg/dl * positive toxicology test * known hypersensitivity to colesevelam hcl or sitagliptin. * any contraindications to a study medication (colesevelam hcl or sitagliptin).

Keywords: colesevelam type 2 diabetes sitagliptin glucose metabolism
radiolabel study in healthy volunteers for insomnia-targeting drug

Conditions: Sleep Initiation and Maintenance Disorders

Summary: the purpose of this study is to define the absorption, breakdown and excretion of a single dose of radiolabelled sb-649868 and its breakdown products by measuring their concentration in blood, urine and faeces over a 7-10 day period. "radiolabelled" means that the test drug has a radioactive component to help us track the drug. the safety and tolerability of the test drug will also be assessed.


Eligibility criteria:
inclusion criteria: * healthy males, aged 30-55 years inclusive. * body weight more or equal to 50kg with a bmi (body mass index) between 18.5-29.9kg/m2 inclusive. * healthy as based on a medical evaluation consisting of medical history, physical examination, lab tests on blood and urine and cardiovascular monitoring. lh, fsh and testosterone hormones must be within normal reference range. exclusion criteria: * positive urine drug screen or alcohol breath test at screening visit. * average weekly alcohol intake of more than 21 units or average daily intake of more than 3 units. * grapefruit or grapefruit juice intake 7 days before dosing and until the last blood sample is taken. * any subject who is not prepared to eat standard meals in the clinic or is a vegetarian. * participated in a clinical trial for a new drug within 30 days or 5 half-lives or twice the duration of that drugs effect before the dosing day for this study. * exposure to 4 new drugs in clinical trials within the last 12 months before dosing in this study. * use of any medications (prescribed or non-prescribed including vitamins and herbal supplements) within 7 days before dosing in this study. * participation in this study would result in the subject donating more than 500ml in a 56 day period. * regular use of tobacco or nicotine-containing products within 6 months of screening. * unwillingness to abstain from sexual intercourse with pregnant or lactating women from dosing until 84 days after. * unwillingness to use contraception and have female partner use contraception if she could become pregnant for 84 days after dosing. * unwillingness to abstain from strenuous physical activity for 48 hours before screening and in the 72 hours before and 48 hours after the treatment period. * administration of radiolabelled substances or exposure to significant radiation (eg serial x-rays or ct scans, barium meal etc)within the past 12 months from screening.

Keywords: distribution, sb-649868, healthy, excretion, sleep disturbances volunteer, metabolism, absorption,
re-feeding gastric residuals in preterm infants

Conditions: Premature; Infant, Light-for-dates

Summary: the purpose of this study is to determine whether re-feeding of gastric residuals reduces the time needed to establish full enteral feedings in premature infants. infants with gestational ages 23-28 weeks at birth will be randomized within one week to receive either gastric residuals or fresh formula or breastmilk whenever significant residuals during feeding advancement require clinical assessment for continuing feedings. primary outcome measure is time to establish full enteral feedings (120cc/kg/day).

infants with gestational ages 23-28 weeks at birth will be randomized within one week to receive either gastric residuals or fresh formula or breastmilk whenever significant residuals during feeding advancement require clinical assessment for continuing feedings. feeding advancement determined by clinical physicians.

Eligibility criteria:
inclusion criteria: 1. gestational age between 23.0 and 28.6 weeks; 2. receiving intravenous fluids but not enteral nutrition more than trophic feeds; 3. written informed consent from the parents exclusion criteria: 1. major congenital/chromosomal anomalies; 2. moribund infant with low likelihood of survival, in the opinion of the clinical team

Keywords: premature infant feeding residuals fresh feeds full feeds digestive system
intranasal remimazolam for premedication in pediatric patient

Conditions: Sedative; Anxiety Disorder

Summary: anesthetic inhalation induction could be one of the most stressful experiences for children during the perioperative period, with almost 50% of them showing anxiety. it is an essential challenge for pediatric anesthesiologists on how to decrease anxiety for children in the operating room (or) environment and to facilitate a smooth induction of anesthesia. various factors like parental separation, unfamiliar surroundings, fear of physicians and needle injections can increase their preoperative anxiety. the researchers conducted the current study to investigate whether intranasal remimazolam can reduce anxiety in children before surgery.

children aged 2-5 years old were randomly allocated into three equal groups based on the premedication routes: group r with intranasal remimazolam, group d with intranasal dexmedetomidine and group p with intranasal placebo, respectively.

Eligibility criteria:
inclusion criteria: 1. with american society of anesthesiologists (asa) physical status i or ii； 2. aged 2-5 years； 3. children with weight for age within the normal range 4. were scheduled surgery with general anesthesia exclusion criteria: 1. children who had gastrointestinal,cardiovascular or endocrine dysfunction; 2. contraindication to preoperative sedation or had a known allergy or hypersensitive reaction to either dexmedetomidine or remimazolam; 3. with any nasal pathology,organ dysfunction; 4. recently respiratory infection, mental disorder; 5. other reasons that researchers hold it is not appropriate to participate in this trial.-

Keywords: remimazolam
study of iodine contrast media extravasation

Conditions: Contrast Media Extravasation

Summary: the purpose of this study is to determine the best intervention after the extravasation of the iodinated contrast medium out of a vessel into the surrounding tissues.

the risk of intravenous extravasation of iodinated contrast media has a relatively low incidence, although the increase in requests for computed tomography scans where it can manage contrasts with a large volume, high osmolality, high-speed injection pumps and even with an added electrical load, has caused an increase in this risk and its complications. when there is an extravasation of iodinated contrast medium, in most published recommendations and guidelines advise local conservative measures, but there is no consensus on whether cold or heat should be applied as the first intervention to minimize the consequences and favour a rapid resolution. this study aims to evaluate the effectiveness of the application of heat in the extravasations of iodinated contrast, providing the necessary evidence to determine the best cure that can be applied in the current circumstances of administration, by injection pumps at high speeds and large volumes.

Eligibility criteria:
inclusion criteria: * computed tomography procedure. * administration of the contrast medium with injection pump between 1,5 and 8 ml/s. * peripheral venous access in the arms or legs. exclusion criteria: * administration of the contrast medium with central venous access. * renal insufficiency. * iodine allergy. * immediate acute complications.

Keywords: iodine iodized computerized tomography extravasation contrast media
effect of anesthesia method on neutrophil-lymphocyte ratio

Conditions: Inflammation; Anesthesia

Summary: the neutrophil/lymphocyte ratio (nlr) is a simple and inexpensive marker of the inflammatory response. nlr is affected not only by surgical trauma but also by the anesthetic method. the method of anesthesia can affect nlr, thereby modulating the inflammatory response and surgical outcomes. in this study, it was aimed to evaluate the relationship between blood nlr and anesthesia techniques in patients undergoing forearm surgery, and the secondary aim was to evaluate the relationship between platelet/lymphocyte ratio (tlr), mean platelet volume (mpv) and anesthesia techniques.


Eligibility criteria:
inclusion criteria: * underwent forearm surgery * between aged 18-70 * under general anesthesia or peripheral nerve block exclusion criteria: * acute infection * morbid obesity * chronic treatment with steroids or immunosuppressants * recently received chemotherapy * hepatic and renal dysfunction; * chronic alcohol abusers * multiple trauma * patients with missing data in their files

Keywords: general anesthesia neutrophil lymphocyte ratio peripheral nerve block
tlr-9 antagonism in steroid resistant optic neuritis

Conditions: Optic Neuritis

Summary: although idiopathic steroid resistant optic neuritis is very uncommon, there is no established treatment protocol for such patients. toll like receptors (tlrs) especially tlr-9 has been shown to play a role in the pathogenesis of optic neuritis. this small case series aims to determine whether immunomodulators directed specifically at tlr-9(i.e. tlr-9 antagonism)play any role in improving the visual function in such patients.


Eligibility criteria:
inclusion criteria: unilateral steroid resistant optic neuritis exclusion criteria: * bilateral optic neuritis * associated systemic disease * prior treatment received

Keywords: best corrected visual acuity pupillary reaction colour vision disc edema
efficacy assessment of lenvatinib associated with pembrolizumab in metastatic endometrial cancer: a french multicentric retrospective early access program-based study

Conditions: Metastatic Endometrial Cancer

Summary: larena is a multicentric retrospective study (secondary use of data) of consecutive patients prospectively registered in the lenvatinib plus pembrolizumab french early access program (temporary authorisation for use). the source of data will be the patient's medical file. we will manually review all files of the participating centers.


Eligibility criteria:
inclusion criteria: * patients having received at least one dose of lenvatinib plus pembrolizumab in the context of the french early access program (temporary authorisation for use) approved by the french health autority. * patients with advanced or recurrent endometrial cancer whose disease is progressing during or following prior platinum-based chemotherapy at any stage and who are not eligible for curative surgery or radiotherapy, according to the french early access program (temporary authorisation for use) approved by the french health autority criteria. exclusion criteria: * patients who refuse the collection and use of their personal data in the course of this research.

Keywords: metastatic endometrial cancer endometrial cancer metastatic cancer
a clinical study to evaluate the efficacy of two siddha drugs sindhuvallathy mezhugu and kalladaippu kudineer for kidney stones

Conditions: Urolithiasis

Summary: this study is a non randomized non comparative study with two siddha formulations sindhuvallathy mezhugu and kalladaippu kudineer are available in siddha classical texts existing for longer period. but there is no scientific data is documented about these formulations. this study aimed to evaluate the efficacy of the study drugs for urolithiasis. after the preliminary drug standardization the clinical study is started at the national institute of siddha tambaram. the primary outcome measure is either the expulsion of stones or changes in the number and size of the stones with 45 days drug treatment.

objectives: primary objectives. to assess the efficacy of sindhu vallathy mezhugu and kalladaippu kudineer in urolithiasis. secondary objectives 1. to standardize the study drugs. 2. to observe the adverse effects if any methods of proposed research: the consists of two segments part - a. non- clinical studies -standardisation of the study drugs. part - b. clinical studies. study drugs 1. sindhu vallathy mezhugu will be prepared as per the literature agasthiar vaidhya vallathy 600. 2. kalldaippu kudineer will be adapted from athmaraktchamirtham ennum vaidhya sarasangeeragam, 1968,page 349, 2.siddha formulary of india part-ii

Eligibility criteria:
inclusion criteria: * age\> 18 years * both gender * diagnosed ultrasonographically/radiographically with visible calculi of \>5mm * with or without clinical symptoms . exclusion criteria: * patients with severe pain and not responding to pain killers * bilateral calculi obstruction requiring immediate surgery, * existing renal failure, * pregnant and lactating women, * age\<18 years, * known hepatic and cardiac diseases, * subjects those who are not willing to give informed consent * women those who are planning for pregnancy .

Keywords: urolithiasis kalladaippu kudineer siddha sindhuvallathy kidney stones